OverviewSuggest Edit

Achaogen is a clinical-stage biopharmaceutical company that discovers and develops drugs to treat multi-drug resistant (MDR), gram-negative infections. The company offers plazomicin for the treatment of serious bacterial infections. It is also developing an oral antibacterial candidate, C-Scape, a combination of an approved beta-lactam and an approved beta-lactamase inhibitor with the potential to treat patients with complicated urinary tract infections (cUTI) due to MDR pathogens.
TypePublic
Founded2004
HQSouth San Francisco, CA, US
Websiteachaogen.com
Employee Ratings3.6

Latest Updates

Revenue (FY, 2018)$8.7 M(-21%)
Share Price (Feb 2021)$0
Cybersecurity ratingAMore

Key People/Management at Achaogen

Blake Wise

Blake Wise

CEO
Janet Dorling

Janet Dorling

Chief Commercial Officer
John W. Smither

John W. Smither

CFO
Show more

Achaogen Office Locations

Achaogen has an office in South San Francisco
South San Francisco, CA, US (HQ)
1 Tower Pl #400
Show all (1)

Achaogen Financials and Metrics

Achaogen Revenue

Achaogen's revenue was reported to be $8.73 m in FY, 2018
USD

Revenue (FY, 2018)

8.7m

Gross profit (FY, 2018)

8.7m

Gross profit margin (FY, 2018), %

99.6%

Net income (FY, 2018)

(186.5m)

EBIT (FY, 2018)

(189.2m)

Market capitalization (26-Feb-2021)

1.9m

Closing stock price (26-Feb-2021)

0.0

Cash (31-Dec-2018)

31.0m

EV

23.9m
Achaogen's current market capitalization is $1.9 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

20.0m26.1m41.8m11.2m8.7m

Revenue growth, %

31%60%

Cost of goods sold

31.0k

Gross profit

8.7m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

6.0m5.2m4.5m4.9m12.0m4.5m5.8m9.1m16.0m7.5m1.3m577.0k2.1m2.6m2.0m

Cost of goods sold

11.0k

Gross profit

2.0m

Gross profit Margin, %

99%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

18.9m20.3m119.0m145.2m31.0m

Accounts Receivable

301.0k

Prepaid Expenses

6.4m1.4m

Inventories

210.1m515.0k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

84.9m74.5m46.9m22.9m39.5m35.1m19.4m54.6m41.8m37.6m144.0m134.7m94.9m63.3m55.6m

Prepaid Expenses

161.0k614.0k727.0k605.0k854.0k1.8m3.4m2.5m3.2m9.0m7.8m6.2m8.9m9.1m6.3m

Inventories

637.0k

Current Assets

91.1m80.4m76.6m66.7m66.6m76.1m57.9m81.3m79.4m147.1m248.2m213.3m161.7m116.8m67.5m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(20.2m)(27.1m)(71.2m)(125.6m)(186.5m)

Depreciation and Amortization

358.0k426.0k441.0k1.3m2.6m

Inventories

(4.9m)

Accounts Payable

5.7m691.0k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(3.5m)(7.0m)(15.3m)(6.2m)(7.1m)(15.8m)(12.2m)(30.5m)(41.5m)(33.3m)(59.3m)(89.2m)(47.2m)(97.2m)(139.0m)

Depreciation and Amortization

88.0k172.0k263.0k99.0k201.0k310.0k121.0k227.0k333.0k113.0k424.0k851.0k561.0k1.3m2.1m

Inventories

(763.0k)

Accounts Payable

211.0k(940.0k)3.0m1.8m1.8m3.3m3.5m7.0m10.1m2.3m(819.0k)(752.0k)(2.4m)6.0m932.0k
USDQ1, 2014

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.2 x
Show all financial metrics

Achaogen Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Achaogen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Achaogen Online and Social Media Presence

Embed Graph

Achaogen News and Updates

Achaogen, Inc. Announces Results of Auction for Substantially All Company Assets

SOUTH SAN FRANCISCO, Calif., June 06, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today it has reached agreements to sell substantially …

Achaogen Plans for Near-Term Sale Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

Bidding process and auction projected to conclude June 2019 Bidding process and auction projected to conclude June 2019

Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

-- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting -- -- Company’s recent restructuring aimed at conserving capital to continue assessment of strategic alternatives --

Achaogen Announces Pricing of $15 Million Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the pricing of an und…

Achaogen Provides Update on Corporate Progress and Key Preliminary Fourth Quarter 2018 Results

-- Company provides update on ZEMDRI® commercialization and launch --  -- Data from both the EPIC and CARE Phase 3 clinical studies of plazomicin are expected in peer-reviewed publication --

Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield

-- Plazomicin may be well-suited to play a critical role in biodefense preparedness -- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address mu…
Show more

Achaogen Blogs

Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 2019

SOUTH SAN FRANCISCO, Calif. , March 13, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it will report

Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine

SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the New England

Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine

-- ZEMDRI is the only once-daily aminoglycoside therapy FDA -approved for use in complicated urinary tract infections (cUTI) -- -- Treatment with ZEMDRI resulted in a greater than four-fold reduction in relapse of cUTI clinical symptoms compared to meropenem at Day 28 -- SOUTH SAN FRANCISCO,

Achaogen Announces Closing of $15 Million Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the completion of its

Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences

-- Leerink February 27, 2019 at 9:30 a.m. ET -- -- Cowen March 12, 2019 at 12:00 p.m. ET -- SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to

Achaogen Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has
Show more

Achaogen Frequently Asked Questions

  • When was Achaogen founded?

    Achaogen was founded in 2004.

  • Who are Achaogen key executives?

    Achaogen's key executives are Blake Wise, Janet Dorling and John W. Smither.

  • What is Achaogen revenue?

    Latest Achaogen annual revenue is $8.7 m.

  • Who are Achaogen competitors?

    Competitors of Achaogen include MyoKardia, Protalex and Biogen.

  • Where is Achaogen headquarters?

    Achaogen headquarters is located at 1 Tower Pl #400, South San Francisco.

  • Where are Achaogen offices?

    Achaogen has an office in South San Francisco.

  • How many offices does Achaogen have?

    Achaogen has 1 office.